Bavarian Nordic A/S
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$164.0M
Doctors Paid
82
Transactions
11,590
2024 Total
$8.4M
Payment Breakdown by Category
Research$163.8M (99.9%)
Consulting$210,444 (0.1%)
Travel$2,294 (0.0%)
Food & Beverage$2,172 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $163.8M | 11,456 | 99.9% |
| Consulting Fee | $210,444 | 48 | 0.1% |
| Travel and Lodging | $2,294 | 4 | 0.0% |
| Food and Beverage | $2,172 | 80 | 0.0% |
| Education | $507.48 | 2 | 0.0% |
Payments by Type
Research
$163.8M
11,456 transactions
General
$215,418
134 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | $61.5M | 0 | 4,730 |
| NCT05238025 | $51.2M | 0 | 2,369 |
| ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | $39.6M | 0 | 1,991 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | $3.2M | 0 | 186 |
| Bavarian Nordic TAEK-VAC-HerBy-001 | $2.3M | 0 | 1,430 |
| Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | $1.6M | 0 | 396 |
| Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years | $1.5M | 0 | 89 |
| POX-MVA-031: Freeze-Dried MVA-BN Lot Consistency Smallpox Trial | $1.1M | 0 | 46 |
| BN-IST-014 | $544,529 | 0 | 2 |
| NCT05329220 | $443,204 | 2 | 109 |
| BRACHY-CHOR-001: BN Brachyury and Radiation in Chordoma | $333,957 | 0 | 57 |
| CV301-BLD-001: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | $113,581 | 0 | 36 |
| WEV-MVA-001: Phase 1 vaccination trial to evaluate safety, tolerability and immunogenicity of a recombinant MVA-BN WEV vaccine in healthy adult subjects | $105,164 | 0 | 2 |
| Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults65 Years | $78,394 | 0 | 6 |
| A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab (MEDI4736) plus CV301 in Combination with Maintenance Chemotherapy for Patients with Metastatic Colorectal or Pancreatic Adenocarcinoma. | $45,600 | 0 | 1 |
| AdjuvantPROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy | $28,800 | 0 | 2 |
| AN OPEN LABEL, RANDOMIZED PHASE 2 TRIAL OF PROSTVAC AND IPILIMUMAB AS MONOTHERAPY OR IN COMBINATION FOR MEN WITH LOCALIZED PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY | $13,300 | 0 | 1 |
| CV301 Clinical Ph 2 Lung | $3,750 | 0 | 1 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 and the product name: CHIKV VLP | $2,483 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatrics | $90,604 | 8 | $11,325 |
| Infectious Disease | $35,231 | 15 | $2,349 |
| Pulmonary Disease | $14,520 | 1 | $14,520 |
| Internal Medicine | $10,037 | 14 | $716.90 |
| Family Medicine | $6,161 | 14 | $440.09 |
| Adult Health | $3,435 | 2 | $1,717 |
| Pediatric Infectious Diseases | $3,274 | 2 | $1,637 |
| Hematology & Oncology | $2,020 | 1 | $2,020 |
| Medical Oncology | $800.00 | 1 | $800.00 |
| Rheumatology | $720.00 | 1 | $720.00 |
| Family | $573.01 | 6 | $95.50 |
| Registered Nurse | $111.74 | 1 | $111.74 |
| Sports Medicine | $69.33 | 2 | $34.67 |
| Emergency Medicine | $65.41 | 2 | $32.71 |
| Anesthesiology | $41.77 | 1 | $41.77 |
| Medical | $41.41 | 1 | $41.41 |
| Pediatric Pulmonology | $41.41 | 1 | $41.41 |
| Specialist | $41.41 | 1 | $41.41 |
| Primary Care | $27.92 | 1 | $27.92 |
| Acute Care | $24.00 | 1 | $24.00 |
| Critical Care Medicine | $24.00 | 1 | $24.00 |
| Hospitalist | $24.00 | 1 | $24.00 |
| Optometrist | $24.00 | 1 | $24.00 |
| Nurse Practitioner | $18.92 | 1 | $18.92 |
| Ophthalmology | $18.92 | 1 | $18.92 |
| Public Health & General Preventive Medicine | $18.92 | 1 | $18.92 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| James Mccarty, M.d, M.D | Pediatrics | Madera, CA | $87,476 | $0 |
| Andrew Shorr, Md, MD | Pulmonary Disease | Washington, DC | $14,520 | $0 |
| Davidson Hamer, Md, MD | Infectious Disease | Boston, MA | $14,409 | $0 |
| Gregory Poland, M.d, M.D | Internal Medicine | Rochester, MN | $7,450 | $0 |
| Dr. Christopher Woods, Md, Mph, MD, MPH | Infectious Disease | Durham, NC | $6,500 | $0 |
| Philip Krause, M.d, M.D | Infectious Disease | Potomac, MD | $5,217 | $0 |
| Dr. Lin Chen, Md, MD | Infectious Disease | Cambridge, MA | $4,035 | $0 |
| Ms. Gail Rosselot, Np, NP | Adult Health | Briarcliff Manor, NY | $3,416 | $0 |
| Myron Levin, Md, MD | Pediatric Infectious Diseases | Aurora, CO | $3,250 | $0 |
| Dr. Donald Middleton, Md, MD | Pediatrics | Pittsburgh, PA | $3,000 | $0 |
| Michael Holzer, Md, MD | Family Medicine | Miami, FL | $2,916 | $0 |
| Dr. Marcus Plescia, Md, MD | Family Medicine | Chapel Hill, NC | $2,916 | $0 |
| Dr. Kathryn Stephenson, M.d, M.D | Internal Medicine | New York, NY | $2,328 | $0 |
| Dr. Larry Anderson, M.d, M.D | Infectious Disease | Atlanta, GA | $2,250 | $0 |
| Dr. Hemant Murthy, M.d, M.D | Hematology & Oncology | Jacksonville, FL | $2,020 | $0 |
| David Snydman, Md, MD | Infectious Disease | Boston, MA | $1,600 | $0 |
| Dr. John Powers, M.d, M.D | Infectious Disease | Olney, MD | $1,000 | $0 |
| Robert Maki, Md, Phd, MD, PHD | Medical Oncology | Philadelphia, PA | $800.00 | $0 |
| Michelle Petri, M.d, M.D | Rheumatology | Baltimore, MD | $720.00 | $0 |
| Alicia Peacock, Fnp, FNP | Family | Lakewood, CO | $349.47 | $0 |
| Anne Murphy | Family | Colorado Springs, CO | $146.28 | $0 |
| Dr. Duellyn Pandis, Dnp, Aprn, Fnp-C, DNP, APRN, FNP-C | Registered Nurse | Tampa, FL | $111.74 | $0 |
| Darvin Smith | Infectious Disease | Redwood City, CA | $71.77 | $0 |
| Michele Raney, M.d, M.D | Anesthesiology | Rancho Mirage, CA | $41.77 | $0 |
| Dr. Julia Calcote, Md, MD | Family Medicine | Claremore, OK | $41.77 | $0 |
About Bavarian Nordic A/S
Bavarian Nordic A/S has made $164.0M in payments to 82 healthcare providers, recorded across 11,590 transactions in the CMS Open Payments database. In 2024, the company paid $8.4M. The top product by payment volume is JYNNEOS ($1.1M).
Payments were distributed across 26 medical specialties. The top specialty by payment amount is Pediatrics ($90,604 to 8 doctors).
Payment categories include: Food & Beverage ($2,172), Consulting ($210,444), Research ($163.8M), Travel & Lodging ($2,294).
Bavarian Nordic A/S is associated with 1 products in the CMS Open Payments database.